Key points
- High-profile global AI executive appointment signals next growth phase for Australian healthtech
- Brad Ryan appointed Chief AI Officer – Former AWS APJ Data & AI Partner Lead and Accenture Managing Director with 30+ years technology leadership experience
- Platform scale now approaching 1 million diagnostic tests across four countries
- Singapore expansion positions i-screen as a regional AI-driven preventive health player
- AI investment focused on earlier detection, personalised screening and longevity insights
Australian-founded health technology company i-screen has appointed senior global technology executive Brad Ryan, GAICD, as Chief AI Officer, strengthening its leadership team as the business deepens its investment in artificial intelligence and data-driven preventive health.
Ryan joins i-screen after more than three decades in senior technology leadership roles, most recently leading the Data and AI partner business for Amazon Web Services across Asia Pacific and Japan. Prior to that, he spent 25 years at Accenture, where he rose to Managing Director and led artificial intelligence programs across ANZ and the broader Asia Pacific region.
The appointment comes at a pivotal point for i-screen. Founded more than a decade ago, the company has quietly built scale across multiple international markets, delivering close to one million diagnostic tests to more than 130,000 people across Australia, New Zealand, Singapore and the United Kingdom. What began as a consumer pathology and screening business is now evolving into a broader technology platform focused on preventive health, early detection and longevity insights.
In his newly created role, Ryan will lead i-screen’s AI, data and technology strategy, with a mandate to embed artificial intelligence more deeply across the company’s screening programs, analytics capabilities and population health initiatives.
i-screen Founder Amelia Thornycroft said the appointment reflects a natural progression for the business after years spent building strong clinical and operational foundations.
“When we started i-screen, the goal was simple - to democratise health screening to support better health decisions,” Thornycroft said. “Over time, we built trusted laboratory partnerships, refined our screening programs and proved we could deliver at scale across multiple countries.
“What’s changed is the opportunity. We now have the data, the reach and the clinical credibility to apply AI in a way that genuinely improves health outcomes. Brad’s experience operating at scale, in complex and regulated environments, makes him the right person to help guide that transition.”
i-screen Group CEO Scott Montgomery said i-screen’s next phase is less about expansion for its own sake and more about extracting deeper insight from the platform it has already built.
“We’ve demonstrated that we can execute - across geographies, across large populations and in partnership with leading clinical providers,” Montgomery said. “The question now is how we responsibly unlock more value from that footprint.
“AI allows us to move beyond static screening toward more predictive and personalised insights. Brad brings the rare combination of strategic perspective and hands-on delivery experience to help us do that properly.”
During his time at AWS, Ryan worked closely with enterprises and technology partners to accelerate the adoption of AI, analytics and machine learning across Asia Pacific. At Accenture, he advised organisations across healthcare, life sciences, consumer goods, natural resources companies and the public sector on large-scale digital transformation, often in highly regulated settings.
Ryan said i-screen stood out because it already had many of the elements required to apply AI meaningfully in healthcare - something he says is often missing in the sector.
“A lot of organisations talk about AI in health, but very few have real-world scale, trusted clinical frameworks and years of execution behind them,” Ryan said. “i-screen does.
“The opportunity here is to use data and AI not as an abstract capability, but as a practical tool for improving people’s lives - helping people understand risk earlier, supporting better decisions and ultimately improving long-term health outcomes.”
Ryan will also join the i-screen Board as a Director, adding technology and governance depth as the company expands its international presence.
A sector at an inflection point
The appointment comes amid accelerating global interest in AI-enabled healthcare, driven by rising healthcare costs, ageing populations and advances in cloud computing and machine learning. Major technology companies including Microsoft and Alphabet have increased investment in healthcare-focused AI infrastructure, while startups and scale-ups race to translate innovation into real-world impact. OpenAI's recent $100 million acquisition of Torch Health in January 2026 underscores accelerating interest from leading AI companies in personalised healthcare solutions.
Industry observers note that companies with established clinical partnerships and access to longitudinal health data are increasingly well positioned as the sector matures - particularly those able to demonstrate both regulatory discipline and execution capability.
i-screen’s leadership believes that balance - between innovation and delivery - will be critical to the next phase of growth in preventive health.
About i-screen
Founded in Australia more than 10 years ago by entrepreneur Amelia Thornycroft, i-screen is a health technology company delivering preventive health screening and data-driven health insights at scale.
The company operates across Australia, New Zealand, Singapore and the United Kingdom, working with leading laboratories, clinicians, employers and partners to deliver evidence-based screening programs across consumer and population health settings. To date, i-screen has delivered close to one million diagnostic tests to more than 130,000 people.
With a growing international footprint and an expanded focus on artificial intelligence, i-screen is positioning itself to play a larger role in the shift toward earlier detection, personalised screening and more sustainable healthcare systems.
For more information, visit www.i-screen.com.au
Contact details:
David Tasker
Chapter One Advisors
T: +61 433 112 936
E: [email protected]